Sector News

Cancer drugmaker Tesaro weighs its options as wannabe buyers come running

February 9, 2017
Life sciences

Industry watchers have been predicting that cancer drugmaker Tesaro would generate M&A buzz. After all, growth-starved Big Pharma players have proven willing to shell out big bucks for prime oncology targets.

And now it has.

The Massachusetts biotech reportedly has attracted takeover interest from a slew of companies eyeing its potential blockbuster niraparib, according to unnamed sources cited by Reuters. Tesaro is discussing its options with investment banks, including Citigroup, though it’s not actually working toward a sale, the sources say.

The reason? The sizeable gap between bid and ask: Tesaro values itself at a much higher price than wannabe buyers currently do. So, for now, Tesaro is getting strategic advice, including tactics for handling its suitors.

That’s not to say the company wouldn’t sell, period. Clinical trial data set to read out this year on PARP prospect niraparib might help bring the parties closer together on price. The up-and-comer has already posted progression-free survival benefits larger than ever before seen in recurrent ovarian cancer, and EvaluatePharma forecast the drug would rake in $1.9 billion in 2022 sales.

The buyer interest is no surprise, considering the prices Big Pharma has paid over the last couple years to add drugs in the fast-growing cancer field. AbbVie, for one, forked over $21 billion for access to a piece of blood-cancer star Imbruvica, while Pfizer coughed up $14 billion for Medivation, maker of fellow PARP candidate talazoparib.

And while Pfizer may have locked up its PARP player with that Medivation buy, plenty of rival bidders lost out. Gilead Sciences was said to be one of them, and Guggenheim analysts last year predicted the California-based Big Biotech could find Tesaro enticing. Earlier this week, Gilead CEO John Milligan conceded that the company would need acquisitions to fuel growth as its hep C standouts plummet.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

January 22, 2023

Sun Pharma to buy Concert Pharmaceuticals for $576m

Life sciences

Sun Pharmaceutical Industries has signed a definitive agreement to buy all outstanding shares of Concert Pharmaceuticals in a deal valued at $576m. Under the deal, the company will buy all shares of Concert common stock through a tender offer for $8.00 per share in cash upfront payment.

January 22, 2023

Novo Nordisk diabetes pill wins FDA approval for first-line use

Life sciences

The Food and Drug Administration on Thursday approved Novo Nordisk’s diabetes pill Rybelsus as an initial treatment to lower blood sugar levels, a label expansion that will allow it to compete more directly with other oral drugs from Merck & Co. and Eli Lilly.

January 22, 2023

Bayer feeling more heat from activist investors, this time from Bluebell

Life sciences

Since making an ill-advised $63 billion buy of Monsanto in 2018, Bayer has faced heaps of pressure from investors that have called for the company to oust its leadership and to restructure. Now comes new pressure from a familiar source. Bluebell Capital Partners has bought an undisclosed stake in the company and is agitating for a breakup, sources told Reuters.

How can we help you?

We're easy to reach